Impact of Muscarinic M^sub 3^ Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study
M3 muscarinic receptor antagonism has been associated with glucose intolerance and disturbance of insulin secretion. Our objective was to examine the risk of type 2 diabetes mellitus (T2DM) in patients using antidepressants with and without M3 muscarinic receptor antagonism (AD_antaM3 and AD_nonanta...
Gespeichert in:
| Veröffentlicht in: | CNS drugs 2017-06, Vol.31 (6), p.483-493 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 493 |
|---|---|
| container_issue | 6 |
| container_start_page | 483 |
| container_title | CNS drugs |
| container_volume | 31 |
| creator | Tran, Yen-Hao Schuiling-Veninga, Catharina C M Bergman, Jorieke E H Groen, Henk Wilffert, Bob |
| description | M3 muscarinic receptor antagonism has been associated with glucose intolerance and disturbance of insulin secretion. Our objective was to examine the risk of type 2 diabetes mellitus (T2DM) in patients using antidepressants with and without M3 muscarinic receptor antagonism (AD_antaM3 and AD_nonantaM3, respectively). We designed a case-control study using a pharmacy prescription database. We selected a cohort of patients who initiated antidepressant use between the ages of 20 and 40 years and who did not receive any anti-diabetic prescriptions at baseline. Cases were defined as those who developed T2DM [i.e., receiving oral anti-diabetic medication, Anatomical Therapeutic Chemical (ATC) code A10B] during the follow-up period (1994-2014), and ten random controls were picked for each case from the cohort of patients who did not develop T2DM. A total of 530 cases with incident T2DM and 5300 controls were included. Compared with no use of antidepressants during the previous 2 years, recent (within the last 6 months) exposure to AD_antaM3 was associated with a moderately increased risk of T2DM: adjusted odds ratio 1.55 (95% confidence interval 1.18-2.02). In the stratified analyses, this association was dose dependent (>365 defined daily doses) and significant for patients who were in the younger age group ( |
| doi_str_mv | 10.1007/s40263-017-0436-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1973393728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1973393728</sourcerecordid><originalsourceid>FETCH-proquest_journals_19733937283</originalsourceid><addsrcrecordid>eNqNi01OwzAQRi0EEuXnAOxGYm2w4ygm7KoAKotKqGTdyk2m4JLawTOR6B04NA3iAKy-J733CXGl1Y1Wyt5SrrLCSKWtVLkp5NeRmGhtS6lLkx__ciatyu2pOCPaKjVWxUR8P-961zDEDcwHalzywTcwX9KwBrOEBTbYc0wwDezeYvC0gxiA3xEWnj7GW73vETJ48G6NjAQ-jLFvsU9I5ALLOqFjbOHFscfAdA9TqByhrGLgFLvu4F55aPcX4mTjOsLLvz0X10-PdTWTfYqfAxKvtnFI4aBWurTGlMZmd-Z_1Q-hV1pb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1973393728</pqid></control><display><type>article</type><title>Impact of Muscarinic M^sub 3^ Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study</title><source>Springer Nature - Complete Springer Journals</source><creator>Tran, Yen-Hao ; Schuiling-Veninga, Catharina C M ; Bergman, Jorieke E H ; Groen, Henk ; Wilffert, Bob</creator><creatorcontrib>Tran, Yen-Hao ; Schuiling-Veninga, Catharina C M ; Bergman, Jorieke E H ; Groen, Henk ; Wilffert, Bob</creatorcontrib><description>M3 muscarinic receptor antagonism has been associated with glucose intolerance and disturbance of insulin secretion. Our objective was to examine the risk of type 2 diabetes mellitus (T2DM) in patients using antidepressants with and without M3 muscarinic receptor antagonism (AD_antaM3 and AD_nonantaM3, respectively). We designed a case-control study using a pharmacy prescription database. We selected a cohort of patients who initiated antidepressant use between the ages of 20 and 40 years and who did not receive any anti-diabetic prescriptions at baseline. Cases were defined as those who developed T2DM [i.e., receiving oral anti-diabetic medication, Anatomical Therapeutic Chemical (ATC) code A10B] during the follow-up period (1994-2014), and ten random controls were picked for each case from the cohort of patients who did not develop T2DM. A total of 530 cases with incident T2DM and 5300 controls were included. Compared with no use of antidepressants during the previous 2 years, recent (within the last 6 months) exposure to AD_antaM3 was associated with a moderately increased risk of T2DM: adjusted odds ratio 1.55 (95% confidence interval 1.18-2.02). In the stratified analyses, this association was dose dependent (>365 defined daily doses) and significant for patients who were in the younger age group (<45 years at the end of followup), were female and had no co-morbidity. On the other hand, recent exposure to AD_nonantaM3 was not associated with a risk for T2DM in any of our analyses. Our results suggest that exposure to AD_antaM3 was associated with the development of T2DM among antidepressant users.</description><identifier>ISSN: 1172-7047</identifier><identifier>EISSN: 1179-1934</identifier><identifier>DOI: 10.1007/s40263-017-0436-x</identifier><language>eng</language><publisher>Auckland: Springer Nature B.V</publisher><subject>Acetylcholine receptors (muscarinic) ; Antidepressants ; Diabetes ; Diabetes mellitus ; Glucose ; Glucose tolerance ; Insulin ; Insulin resistance ; Insulin secretion ; Intolerance ; Morbidity ; Patients ; Pharmacy ; Population ; Prescription drugs ; Psychotropic drugs ; Secretion</subject><ispartof>CNS drugs, 2017-06, Vol.31 (6), p.483-493</ispartof><rights>Copyright Springer Science & Business Media Jun 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Tran, Yen-Hao</creatorcontrib><creatorcontrib>Schuiling-Veninga, Catharina C M</creatorcontrib><creatorcontrib>Bergman, Jorieke E H</creatorcontrib><creatorcontrib>Groen, Henk</creatorcontrib><creatorcontrib>Wilffert, Bob</creatorcontrib><title>Impact of Muscarinic M^sub 3^ Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study</title><title>CNS drugs</title><description>M3 muscarinic receptor antagonism has been associated with glucose intolerance and disturbance of insulin secretion. Our objective was to examine the risk of type 2 diabetes mellitus (T2DM) in patients using antidepressants with and without M3 muscarinic receptor antagonism (AD_antaM3 and AD_nonantaM3, respectively). We designed a case-control study using a pharmacy prescription database. We selected a cohort of patients who initiated antidepressant use between the ages of 20 and 40 years and who did not receive any anti-diabetic prescriptions at baseline. Cases were defined as those who developed T2DM [i.e., receiving oral anti-diabetic medication, Anatomical Therapeutic Chemical (ATC) code A10B] during the follow-up period (1994-2014), and ten random controls were picked for each case from the cohort of patients who did not develop T2DM. A total of 530 cases with incident T2DM and 5300 controls were included. Compared with no use of antidepressants during the previous 2 years, recent (within the last 6 months) exposure to AD_antaM3 was associated with a moderately increased risk of T2DM: adjusted odds ratio 1.55 (95% confidence interval 1.18-2.02). In the stratified analyses, this association was dose dependent (>365 defined daily doses) and significant for patients who were in the younger age group (<45 years at the end of followup), were female and had no co-morbidity. On the other hand, recent exposure to AD_nonantaM3 was not associated with a risk for T2DM in any of our analyses. Our results suggest that exposure to AD_antaM3 was associated with the development of T2DM among antidepressant users.</description><subject>Acetylcholine receptors (muscarinic)</subject><subject>Antidepressants</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Glucose</subject><subject>Glucose tolerance</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Insulin secretion</subject><subject>Intolerance</subject><subject>Morbidity</subject><subject>Patients</subject><subject>Pharmacy</subject><subject>Population</subject><subject>Prescription drugs</subject><subject>Psychotropic drugs</subject><subject>Secretion</subject><issn>1172-7047</issn><issn>1179-1934</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqNi01OwzAQRi0EEuXnAOxGYm2w4ygm7KoAKotKqGTdyk2m4JLawTOR6B04NA3iAKy-J733CXGl1Y1Wyt5SrrLCSKWtVLkp5NeRmGhtS6lLkx__ciatyu2pOCPaKjVWxUR8P-961zDEDcwHalzywTcwX9KwBrOEBTbYc0wwDezeYvC0gxiA3xEWnj7GW73vETJ48G6NjAQ-jLFvsU9I5ALLOqFjbOHFscfAdA9TqByhrGLgFLvu4F55aPcX4mTjOsLLvz0X10-PdTWTfYqfAxKvtnFI4aBWurTGlMZmd-Z_1Q-hV1pb</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Tran, Yen-Hao</creator><creator>Schuiling-Veninga, Catharina C M</creator><creator>Bergman, Jorieke E H</creator><creator>Groen, Henk</creator><creator>Wilffert, Bob</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>4T-</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20170601</creationdate><title>Impact of Muscarinic M^sub 3^ Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study</title><author>Tran, Yen-Hao ; Schuiling-Veninga, Catharina C M ; Bergman, Jorieke E H ; Groen, Henk ; Wilffert, Bob</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_19733937283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acetylcholine receptors (muscarinic)</topic><topic>Antidepressants</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Glucose</topic><topic>Glucose tolerance</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Insulin secretion</topic><topic>Intolerance</topic><topic>Morbidity</topic><topic>Patients</topic><topic>Pharmacy</topic><topic>Population</topic><topic>Prescription drugs</topic><topic>Psychotropic drugs</topic><topic>Secretion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tran, Yen-Hao</creatorcontrib><creatorcontrib>Schuiling-Veninga, Catharina C M</creatorcontrib><creatorcontrib>Bergman, Jorieke E H</creatorcontrib><creatorcontrib>Groen, Henk</creatorcontrib><creatorcontrib>Wilffert, Bob</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>CNS drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tran, Yen-Hao</au><au>Schuiling-Veninga, Catharina C M</au><au>Bergman, Jorieke E H</au><au>Groen, Henk</au><au>Wilffert, Bob</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Muscarinic M^sub 3^ Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study</atitle><jtitle>CNS drugs</jtitle><date>2017-06-01</date><risdate>2017</risdate><volume>31</volume><issue>6</issue><spage>483</spage><epage>493</epage><pages>483-493</pages><issn>1172-7047</issn><eissn>1179-1934</eissn><abstract>M3 muscarinic receptor antagonism has been associated with glucose intolerance and disturbance of insulin secretion. Our objective was to examine the risk of type 2 diabetes mellitus (T2DM) in patients using antidepressants with and without M3 muscarinic receptor antagonism (AD_antaM3 and AD_nonantaM3, respectively). We designed a case-control study using a pharmacy prescription database. We selected a cohort of patients who initiated antidepressant use between the ages of 20 and 40 years and who did not receive any anti-diabetic prescriptions at baseline. Cases were defined as those who developed T2DM [i.e., receiving oral anti-diabetic medication, Anatomical Therapeutic Chemical (ATC) code A10B] during the follow-up period (1994-2014), and ten random controls were picked for each case from the cohort of patients who did not develop T2DM. A total of 530 cases with incident T2DM and 5300 controls were included. Compared with no use of antidepressants during the previous 2 years, recent (within the last 6 months) exposure to AD_antaM3 was associated with a moderately increased risk of T2DM: adjusted odds ratio 1.55 (95% confidence interval 1.18-2.02). In the stratified analyses, this association was dose dependent (>365 defined daily doses) and significant for patients who were in the younger age group (<45 years at the end of followup), were female and had no co-morbidity. On the other hand, recent exposure to AD_nonantaM3 was not associated with a risk for T2DM in any of our analyses. Our results suggest that exposure to AD_antaM3 was associated with the development of T2DM among antidepressant users.</abstract><cop>Auckland</cop><pub>Springer Nature B.V</pub><doi>10.1007/s40263-017-0436-x</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1172-7047 |
| ispartof | CNS drugs, 2017-06, Vol.31 (6), p.483-493 |
| issn | 1172-7047 1179-1934 |
| language | eng |
| recordid | cdi_proquest_journals_1973393728 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Acetylcholine receptors (muscarinic) Antidepressants Diabetes Diabetes mellitus Glucose Glucose tolerance Insulin Insulin resistance Insulin secretion Intolerance Morbidity Patients Pharmacy Population Prescription drugs Psychotropic drugs Secretion |
| title | Impact of Muscarinic M^sub 3^ Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A12%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Muscarinic%20M%5Esub%203%5E%20Receptor%20Antagonism%20on%20the%20Risk%20of%20Type%202%20Diabetes%20in%20Antidepressant-Treated%20Patients:%20A%20Case-Controlled%20Study&rft.jtitle=CNS%20drugs&rft.au=Tran,%20Yen-Hao&rft.date=2017-06-01&rft.volume=31&rft.issue=6&rft.spage=483&rft.epage=493&rft.pages=483-493&rft.issn=1172-7047&rft.eissn=1179-1934&rft_id=info:doi/10.1007/s40263-017-0436-x&rft_dat=%3Cproquest%3E1973393728%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1973393728&rft_id=info:pmid/&rfr_iscdi=true |